Chasing Pfizer, Sarepta Prepares To Launch Pivotal Duchenne Gene Therapy Trial
Investors Still Skeptical
Executive Summary
Sarepta believes it is still very much in the running with its gene therapy but is playing down talk of an accelerated approval based on biomarker data.
You may also be interested in...
Sarepta Leapfrogs Pfizer In The US, Launching DMD Gene Therapy Pivotal Trial
The company has initiated the first pivotal double-blind gene therapy trial in DMD in the US in a tight race with Pfizer.
Sarepta Sinks On Mixed DMD Gene Therapy Study
Any time advantage Sarepta's Duchenne muscular dystrophy gene therapy may have had over rivals, notably Pfizer, has disappeared after SRP-9001 failed to significantly improve muscle function in a closely watched trial.
Investors Take Flight After Bluebird Bio’s Sickle Cell Delay
Bluebird’s first two gene therapies are on the market, but a new delay to its biggest hope, the sickle cell disease candidate lovo-cell, has spooked investors.